Actionable news
All posts from Actionable news
Actionable news in GSM: Globe Specialty Metals Inc.,

Stifel Has 3 Top Stocks to Buy With 95% or More Upside Potential

Everybody likes to look for the home run stocks, and with good reason. Hitting the long ball on a stock pick brings in stellar capital gains and can help a moribund portfolio look real good, real fast. The danger for many investors is putting too big a bet on a stock looking for big gains. The smart things to do when finding an idea that has big upside potential, but could have big downside if a catalyst is not met, is to put on a small position, that can be increased if the positives are indeed there.

We recently reviewed some top picks from Stifel, and found three companies the firm likes that have massive upside potential. While not suitable for all accounts, these three companies make good sense for investors that have capital that can be placed on aggressive trades. All are rated Buy at Stifel.


This top biotech has been absolutely eviscerated since printing highs last summer. Cempra Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia, and new drug applications for the intravenous and oral capsule formulations have been submitted to the FDA.

Solithromycin is licensed to company’s strategic commercial partner Toyama Chemical, a subsidiary of Fujifilm Holdings, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.

The company recently released very positive results for a Phase 2, multi-center, randomized, double-blind study that was conducted...